



Press release

Global Life Science Ventures invests into Cyberkinetics, Inc.

London/Zug/Munich, 9 July 2003 – *Global Life Science Ventures (GLSV)* today announces that it has made a US\$ 2 million investment in neurotechnology company Cyberkinetics, Inc. GLSV participated in the Series A private financing round for Cyberkinetics, which raised US\$ 9.3 million, as part of a syndicate of international investors including Oxford Bioscience Partners and Neuroventures Capital LLC. Philip Morgan, the London, UK-based Partner of GLSV, will join the Cyberkinetics' Board of Directors.

Cyberkinetics, Foxborough, MA, is active in the emerging field of neurotechnology. Founded in 2001, Cyberkinetics underwent a merger in late 2002 with Bionic Technologies, LLC, a leading provider of neural recording, stimulation and signal processing equipment for neuroscience research. Cyberkinetics is developing innovative devices for the treatment of nervous system dysfunction by combining recent advances in neuroscience, computer science and engineering.

Cyberkinetics' proprietary neurotechnology platform includes implantable devices that have the potential to control movement or communication via other external devices. The company's brain-computer interfaces have a broad potential not only for paralyzed or physically impaired humans, but also as new devices to detect and treat neurological conditions such as stroke or epilepsy.

"Cyberkinetics has quickly established itself as a company offering truly innovative technological solutions in a newly emerging sector of the Life Science industry," says Philip Morgan, Partner of Global Life Science Ventures. "With its considerable clinical potential, strong intellectual property position and outstanding management team, we believe the company adds considerable value to our portfolio."

"Global Life Science Ventures' strong international ties bring tremendous value to Cyberkinetics as we build a leadership position in the rapidly emerging market of direct brain-computer medical device interfaces to assist patients in overcoming severe disabilities and other neurological disorders," stated Tim Surgenor, President and CEO of Cyberkinetics. "This financing provides the resources to build on our leading intellectual property position and expand our clinical and regulatory expertise, as we are on track to begin human clinical studies of our BrainGate Neural Interface Device early next year."



About Global Life Science Ventures:

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany, Switzerland and the UK, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than €200 million. Up to now, GLSV has financed 20 leading biotechnology companies, four of which have completed a successful exit through IPO or trade-sale. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.

Global Life Science Ventures – one team – three locations – global perspective

UK

GLSV Ltd.
1, Northumberland Avenue
London WC2N 5BW, UK
Tel. +44 (0)20 89 38 66 92
Fax +44 (0)20 89 38 77 40

Switzerland

GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel. +41 (0)41 727 19 40
Fax +41 (0)41 727 19 45

Germany

GLSV GmbH
Von-der-Tann-Str. 3
D – 80539 München
Tel. +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30

www.glsv-vc.com
mailbox@glsv-vc.com

For additional information, please contact:

Rochat & Partners

Christophe Lamps
Tel. +41 22 718 37 46
Fax +41 22 786 54 58
E-mail: clamps@rochat-pr.ch